Clinical Trials 101 | Alzheimer's Prevention Registry

You are here

Home

Clinical Trials 101

Independent committees help to keep trial participants safe

Who is watching out for your safety in a clinical trial?  Learn how independent data safety monitoring boards are used to evaluate the safety of the trial and make sure participants are protected.

How was a woman destined to get Alzheimer’s protected by her genes?

A woman in Colombia was destined to develop Alzheimer’s disease in her 40’s because of a rare family genetic mutation. But she didn’t show symptoms until her 70’s. Scientists are now investigating what protected her from the memory stealing disease. Could her genes hold the key to new treatments?

For Alzheimer’s Patient, Hope Renewed Following Biogen Announcement

When biotechnology company Biogen announced the cancellation of the trial for their Alzheimer’s drug aducanumab, nearly 3,500 trial participants were left in limbo. Now, following the company’s announcement that they will be reviving the trial, hope is blooming once again, particularly for those who felt the drug had a positive effect on their lives.

Drug curbs delusions, eases anger in Alzheimer's patients, researchers find

If regulators approve it, the drug could become the first new medicine for Alzheimer's patients in nearly two decades.
 

Reassessment of Alzheimer’s Drug Raises Hope—and Concerns

Pharmaceutical giant Biogen now admits that it made a mistake back in March when it stopped a pair of trials of an experimental Alzheimer’s drug. A deep analysis of the data, released Thursday, suggests the drug, called aducanumab, did make a difference for patients who took the highest dose for the longest period of time—but only in one of two studies.

Drugmaker reverses course, plans to seek FDA approval for Alzheimer's treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment for early Alzheimer's disease, Biogen and its Japanese partner Eisai announced on Tuesday.

We Will Find a Breakthrough for Alzheimer's Disease

I have spent my entire career interested in the mysteries of the brain: what it looks like, how it works and what happens when it doesn’t. Alzheimer’s disease has been the primary focus of my professional life, starting as a young researcher looking at brain scans, and leading up to now, as the head of the research program at the Alzheimer’s Association.

MRI may help doctors differentiate causes of memory loss

A UCLA-led study has found that MRI scans can help doctors distinguish whether a person's memory loss is being caused by Alzheimer's disease or by traumatic brain injury.

Biogen Dropped Me From Their Cancelled Alzheimer’s Study; Now They’re Bringing It Back

I wasn’t yet fully awake this morning when I started poking through my Facebook feed and saw the head-spinning news that Biogen had reversed itself and was now asking the FDA to approve its experimental Alzheimer’s drug.

PROMOTING HEALTHY BEHAVIOR

Amy Bleakley's research runs the gamut from adolescents to Alzheimer's disease, dental cavities to clinical trials, but she says the topics are not as different as they might appear.